Assignee
JANSSEN BIOTECH INC
US·335 granted patents·437 pending applications·1,157 citations·filing 2008–2025
Top patents by PatentIndex Score
772 records- 0197US11713355B2Anti-CD38 antibodies for treatment of acute lymphoblastic leukemiaJANSSEN BIOTECH INC·Filed 2020·Granted Aug 1, 2023·5 cites·18 claims
- 0297US11576986B2Macrocyclic chelators and methods of use thereofJANSSEN BIOTECH INC·Filed 2020·Granted Feb 14, 2023·9 cites·22 claims
- 0397US11566079B2Subcutaneous formulations of anti-CD38 antibodies and their usesJANSSEN BIOTECH INC·Filed 2020·Granted Jan 31, 2023·14 cites·37 claims
- 0497US10385135B2Subcutaneous formulations of anti-CD38 antibodies and their usesJANSSEN BIOTECH INC·Filed 2016·Granted Aug 20, 2019·27 cites·37 claims
- 0597US10138465B2Differentiation of human embryonic stem cells into pancreatic endocrine cells using HB9 regulatorsJANSSEN BIOTECH INC·Filed 2013·Granted Nov 27, 2018·22 cites·53 claims
- 0697US7993645B2Human anti-IL-23 antibodies, compositions, methods and usesJANSSEN BIOTECH INC·Filed 2010·Granted Aug 9, 2011·57 cites·11 claims
- 0796US11732051B2Subcutaneous formulations of anti-CD38 antibodies and their usesJANSSEN BIOTECH INC·Filed 2020·Granted Aug 22, 2023·6 cites·20 claims
- 0896US11708420B2Subcutaneous formulations of anti-CD38 antibodies and their usesJANSSEN BIOTECH INC·Filed 2020·Granted Jul 25, 2023·6 cites·37 claims
- 0996US11708419B2Subcutaneous formulations of anti-CD38 antibodies and their usesJANSSEN BIOTECH INC·Filed 2020·Granted Jul 25, 2023·6 cites·37 claims
- 1096US10800851B2Combination therapies with anti-CD38 antibodiesJANSSEN BIOTECH INC·Filed 2017·Granted Oct 13, 2020·12 cites·16 claims
- 1196US10358628B2Differentiation of human embryonic stem cells into single hormonal insulin positive cellsJANSSEN BIOTECH INC·Filed 2015·Granted Jul 23, 2019·10 cites·35 claims
- 1296US10053513B2Antibody Fc mutants with ablated effector functionsJANSSEN BIOTECH INC·Filed 2015·Granted Aug 21, 2018·15 cites·5 claims
- 1396US9897612B2Fibronectin type III repeat based protein scaffolds with alternative binding surfacesJANSSEN BIOTECH INC·Filed 2015·Granted Feb 20, 2018·12 cites·7 claims
- 1496US9637549B2Antibody Fc mutants with ablated effector functionsJANSSEN BIOTECH INC·Filed 2015·Granted May 2, 2017·8 cites·1 claims
- 1596US9603927B2Combination therapies with anti-CD38 antibodiesJANSSEN BIOTECH INC·Filed 2015·Granted Mar 28, 2017·31 cites·18 claims
- 1696US9102737B2Human anti-CD27 antibodies, methods and usesJANSSEN BIOTECH INC·Filed 2013·Granted Aug 11, 2015·36 cites·16 claims
- 1795US12060432B2Combination therapies with anti-CD38 antibodiesJANSSEN BIOTECH INC·Filed 2020·Granted Aug 13, 2024·3 cites·20 claims
- 1895US11299534B2CD8A-binding fibronectin type III domainsJANSSEN BIOTECH INC·Filed 2020·Granted Apr 12, 2022·4 cites·20 claims
- 1995US10947511B2Differentiation of human embryonic stem cells into pancreatic endocrine cells using thyroid hormone and/or alk5, an inhibitor of tgf-beta type 1 receptorJANSSEN BIOTECH INC·Filed 2018·Granted Mar 16, 2021·6 cites·12 claims
- 2095US10925932B2Serum albumin-binding fibronectin type III domainsJANSSEN BIOTECH INC·Filed 2017·Granted Feb 23, 2021·8 cites·16 claims
- 2195US10781261B2Subcutaneous formulations of anti-CD38 antibodies and their usesJANSSEN BIOTECH INC·Filed 2019·Granted Sep 22, 2020·17 cites·37 claims
- 2295US10626165B2CD8a-binding fibronectin type III domainsJANSSEN BIOTECH INC·Filed 2017·Granted Apr 21, 2020·14 cites·19 claims
- 2395US9732154B2Anti-CD38 antibodies for treatment of acute lymphoblastic leukemiaJANSSEN BIOTECH INC·Filed 2015·Granted Aug 15, 2017·21 cites·16 claims
- 2495US9593164B2Bispecific EGFR/c-Met antibodiesJANSSEN BIOTECH INC·Filed 2013·Granted Mar 14, 2017·34 cites·2 claims
- 2594US11932680B2CD8A-binding fibronectin type III domainsJANSSEN BIOTECH INC·Filed 2022·Granted Mar 19, 2024·2 cites·4 claims
- 2694US11845808B2Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesJANSSEN BIOTECH INC·Filed 2021·Granted Dec 19, 2023·3 cites·30 claims
- 2794US10899833B2Human antibody specific for interleukin-1 alphaJANSSEN BIOTECH INC·Filed 2017·Granted Jan 26, 2021·4 cites·12 claims
- 2894US10668149B2Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitorsJANSSEN BIOTECH INC·Filed 2016·Granted Jun 2, 2020·16 cites·6 claims
- 2994US10597438B2PD-L1 binding fibronectin type III domainsJANSSEN BIOTECH INC·Filed 2017·Granted Mar 24, 2020·12 cites·17 claims
- 3094US10556961B2Anti-CD38 antibodies for treatment of acute lymphoblastic leukemiaJANSSEN BIOTECH INC·Filed 2017·Granted Feb 11, 2020·17 cites·18 claims
- 3194US10494609B2Use of a TGF-βR-1 kinase to produce human pancreatic endocrine cellsJANSSEN BIOTECH INC·Filed 2018·Granted Dec 3, 2019·9 cites·16 claims
- 3294US10259867B2Method for treating lupus by administering an anti-IL-12 antibodyJANSSEN BIOTECH INC·Filed 2017·Granted Apr 16, 2019·7 cites·16 claims
- 3394US10030070B2Human anti-IL-23 antibodies, compositions, methods and usesJANSSEN BIOTECH INC·Filed 2017·Granted Jul 24, 2018·11 cites·11 claims
- 3494US9783607B2Human anti-IL-23 antibodies, compositions, methods and usesJANSSEN BIOTECH INC·Filed 2016·Granted Oct 10, 2017·10 cites·19 claims
- 3594US9321836B2Anti-TNF antibodies, compositions, methods and usesJANSSEN BIOTECH INC·Filed 2014·Granted Apr 26, 2016·15 cites·4 claims
- 3693US11365244B2Anti-PHF-tau antibodies and uses thereofJANSSEN BIOTECH INC·Filed 2020·Granted Jun 21, 2022·4 cites·14 claims
- 3793US10766953B2Anti-PHF-tau antibodies and uses thereofJANSSEN BIOTECH INC·Filed 2018·Granted Sep 8, 2020·12 cites·40 claims
- 3893US10006006B2Use of small molecules to enhance MAFA expression in pancreatic endocrine cellsJANSSEN BIOTECH INC·Filed 2015·Granted Jun 26, 2018·7 cites·20 claims
- 3993US9580508B2Bispecific EGFR/c-Met antibodiesJANSSEN BIOTECH INC·Filed 2014·Granted Feb 28, 2017·19 cites·22 claims
- 4092US12091466B2Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignanciesJANSSEN BIOTECH INC·Filed 2020·Granted Sep 17, 2024·3 cites·18 claims
- 4192US11746161B2Antibodies that specifically bind PD-1 and methods of useJANSSEN BIOTECH INC·Filed 2020·Granted Sep 5, 2023·3 cites·15 claims
- 4292US11021543B2Immune modulation and treatment of solid tumors with antibodies that specifically bind CD38JANSSEN BIOTECH INC·Filed 2018·Granted Jun 1, 2021·13 cites·19 claims
- 4392US10766965B2Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignanciesJANSSEN BIOTECH INC·Filed 2016·Granted Sep 8, 2020·15 cites·33 claims
- 4492US9090694B2ST2L antibody antagonistsJANSSEN BIOTECH INC·Filed 2013·Granted Jul 28, 2015·19 cites·4 claims
- 4592US2025388693A1Subcutaneous Formulations Of Anti-CD38 Antibodies And Their UsesJANSSEN BIOTECH INC·Filed 2025·Application pending·0 cites
- 4691US12084501B2Proteins comprising CD3 antigen binding domains and uses thereofJANSSEN BIOTECH INC·Filed 2022·Granted Sep 10, 2024·2 cites·44 claims
- 4791US12077592B2GPRC5D chimeric antigen receptors and cells expressing the sameJANSSEN BIOTECH INC·Filed 2020·Granted Sep 3, 2024·3 cites·36 claims
- 4891US11667712B2Materials and methods for modulating t cell mediated immunityJANSSEN BIOTECH INC·Filed 2020·Granted Jun 6, 2023·2 cites·41 claims
- 4991US11618787B2Methods of treating high risk multiple myelomaJANSSEN BIOTECH INC·Filed 2018·Granted Apr 4, 2023·10 cites·12 claims
- 5091US11459391B2Combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodiesJANSSEN BIOTECH INC·Filed 2020·Granted Oct 4, 2022·7 cites·27 claims
Showing the top 50 of 772 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when JANSSEN BIOTECH INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →